This content is from: Home

Biosimilars highlighted in controversial trade talks

The co-sponsor of the Hatch-Waxman Act has said he opposes any inclusion of US policy on exclusivity for biosimilars in Free Trade Agreement negotiations with Asia-Pacific countries

To access our in-house intelligence please request a trial here.

Read this article – and more – for a 30 day period.


Are you already an Managing IP subscriber? Login here


Instant access to all of our content. Membership Options | 30 Day Trial